Allozymes applies its proprietary platform technology to rapidly develop novel enzymes, revolutionizing the way that industries manufacture complex natural products.

Akbar Vahidi

Peyman Salehian

Allozymes

Evolva Holding SA discovers, researches, develops, and commercializes nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. It offers various ingredients comprising Veri-te Resveratrol, a nature-made polyphenol that occurs naturally in grapes and other plants, including peanuts, cranberries, and berries; L-Arabinose, a flavoring agent used in Maillard reaction; Valencene, an aroma component of citrus fruit and citrus-derived odorants; Nootkatone, an aroma ingredient of grapefruit obtained via biochemical oxidation of valencene; and Vanillin, a primary component of vanilla bean extract. The company was founded in 2004 and is headquartered in Reinach, Switzerland.

Neil Goldsmith

Soren V.S. Nielsen

Alexandra SantAna Sorensen

Evolva Holding SA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

LanzaTech Global, Inc. operates as a nature-based carbon refining company in the United States and internationally. The company transforms waste carbon into the chemical building blocks for consumer goods, such as sustainable fuels, fabrics, and packaging. LanzaTech Global, Inc. was founded in 2005 and is headquartered in Skokie, Illinois.

Sean Simpson

LanzaTech Global, Inc.

Allozymes is a leading deep technology company that applies its proprietary microfluidics technology to develop custom-designed enzymes for cleaner and sustainable manufacturing of complex natural products. Allozymes’ interdisciplinary innovation enables 10x faster enzyme engineering with a 200x higher chance of success compared to robotics which enables breakthrough development in a wide range of industries.


SOSV

Xora Innovation

TI Platform Management

Entrepreneur First

Passionate about sustainability? Ignite your career with our vibrant community. Connect with like-minded minds, uncover hidden opportunities, and land your dream job through our Telegram channel ✌ 

Dive in ⬇ 

#Allozymes #ScienceConnections #CareerGrowth 

It’s yeast-o’clock somewhere in the world!

Here’s some lycopene at work creating different colors. Science is indeed beautiful ✨ 

#Allozymes #Biotechnology #LabLife

Metric
Company Name	Allozymes	Evolva Holding SA	Ginkgo Bioworks Holdings, Inc.	LanzaTech Global, Inc.
Symbol		EVE	DNA	LNZA
MSH ID	COM:ALLOZYMES	COM:EVOLVA	COM:GINKGOBIOWORKS	COM:LANZATECH
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Technology		Healthcare	Industrials
Industry	Biotechnology		Biotechnology	Waste Management
Country	SG	CH	US	US
Stage			Grant
Employee Count	29	49	1.22K	414
Website	allozymes.com	evolva.com	ginkgobioworks.com	lanzatech.com
LinkedIn			ginkgo-bioworks
Founders

Metric
Market Cap	5.58M	725.64M	359.88M
Enterprise Value
Monthly Web Traffic	6.70K	20.69K
Web Traffic Growth	8.09	-0.17
Valuation
Raised Capital	540K

Metric
Revenue	4.74M	251.46M	62.63M
Revenue (LTM)
Revenue (NTM)
Gross Profit	4.74M	142.64M	12.20M
EBITDA	6.51M	-600.68M	-100.93M
Operating Income	577.03K	-672.23M	-106.38M
Net Income	-115.38M	-892.87M	-134.10M
EPS	-16.00	-0.46	-0.76
Diluted EPS	-16.00	-0.46	-0.76
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.53	0.75	0.41
Operating Profit Margin	16.43	-3.34	-1.36
EBITDA Margin	1.37	-2.39	-1.61
Net Profit Margin	-7.94	-3.55	-1.44
Return on Equity	-1.39	-0.65	-0.70
Return on Assets	-1.77	-0.54	-0.45
Return on Capital Employed	9.58	-0.51	-0.48

COM:ALLOZYMES

Allozymes

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-15.44	-2.78	-5.03
P/B Ratio	6.21	1.90	5.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.75	93.70	9.58
EV Multiple	1.84	-1.34	-3.13

Metric
Days Sales Outstanding	111.25	73.17	766.17
Days Payables Outstanding	71.53	50.57	63.94
Days Inventory Outstanding	320.02	0.27	42.00
Operating Cycle	413.41	46.33	271.59
Cash Conversion Cycle	362.34	-7.39	239.68
Asset Turnover	0.42	0.15	0.32

Metric
Operating Cash Flow	-3.08M	-295.50M	-97.30M
Free Cash Flow	-3.08M	-336.30M	-105.85M
Cash Flow to Debt		-0.63	-2.76
Operating Cash Flow/Sales	-0.65	-1.14	-0.98
Free Cash Flow Yield	-4.76	-0.16	-0.02

Metric
Cash & Equivalents	6.66M	948.86M	76.28M
Accounts Receivable		50.07M	-9.95M
Inventory		46K	5.34M
Goodwill		49.24M
Debt to Capitalization	0.37	0.35	0.30
Debt to Assets	0.11	0.20	0.03
Current Ratio	1.61	6.78	5.26
Quick Ratio	3.65	5.98	6.89

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.08	0.94	0.73
R&D to Revenue	1.52	2.05	3.16
SG&A to Revenue	0.20	1.32